Moza MPS 125/5mg Chewable Tablet 10s

Moza MPS 125/5mg Chewable Tablet 10s combines dimethicone (simethicone) and mosapride, providing complementary antiflatulent and prokinetic actions to improve digestive comfort and gastrointestinal motility.

Dimethicone, also known as simethicone, is an antiflatulent agent that works by reducing the surface tension of gas bubbles in the gastrointestinal tract. This allows trapped gas bubbles to combine and pass more easily through belching or flatulence, relieving bloating, abdominal pressure, fullness, and discomfort associated with excessive intestinal gas. Simethicone is not systemically absorbed and acts locally within the digestive tract.

Mosapride is a selective serotonin 5-HT4 receptor agonist with prokinetic activity. It enhances the release of acetylcholine within the enteric nervous system, thereby stimulating gastrointestinal motility and accelerating gastric emptying. Mosapride helps improve symptoms such as indigestion, early satiety, nausea, abdominal fullness, and reflux associated with impaired gastric motility.

The combination of simethicone and mosapride is particularly useful in patients with functional dyspepsia, gastric bloating, gastroesophageal reflux symptoms, and motility-related digestive discomfort. While simethicone relieves gaseous distension and abdominal pressure, mosapride improves coordinated gastrointestinal movement, helping food and gas pass more efficiently through the digestive system.

Moza MPS 125/5mg Chewable Tablet 10s is commonly prescribed for conditions involving excessive gas formation, bloating, functional dyspepsia, delayed gastric emptying, and gastrointestinal motility disturbances. Proper use along with dietary modifications may help improve digestive comfort and quality of life.

The uses of Moza MPS 125/5mg Chewable Tablet 10s are as follows:

Functional Dyspepsia

Moza MPS 125/5mg Chewable Tablet 10s is used to relieve indigestion, upper abdominal discomfort, fullness, and post-meal heaviness associated with impaired gastric motility.

Abdominal Bloating and Gas

It helps reduce bloating, gaseous distension, and discomfort caused by excessive gastrointestinal gas accumulation.

Gastroesophageal Reflux Symptoms

Mosapride improves gastric emptying and may help reduce reflux-related symptoms such as belching and post-meal discomfort.

Delayed Gastric Emptying

It supports improved gastrointestinal movement in patients with sluggish gastric motility or mild gastroparesis-related symptoms.

Post-Meal Fullness and Early Satiety

The combination helps relieve the sensation of prolonged fullness after meals.

Digestive Discomfort Associated with Gas

Simethicone helps disperse trapped gas bubbles, improving abdominal comfort and reducing pressure sensations.

Here are the benefits of Moza MPS 125/5mg Chewable Tablet 10s:

• Relieves Abdominal Bloating and Gas: Simethicone helps break down trapped gas bubbles, reducing bloating, abdominal pressure, and discomfort.

• Improves Gastrointestinal Motility: Mosapride enhances coordinated stomach and intestinal movement, promoting smoother digestion and gastric emptying.

• Reduces Post-Meal Fullness: The combination helps relieve heaviness, fullness, and discomfort experienced after meals.

• Supports Functional Dyspepsia Management: Helps improve symptoms such as indigestion, nausea, belching, and upper abdominal discomfort associated with impaired motility.

• Dual-Action Digestive Relief: Combines antiflatulent and prokinetic actions to address both gas accumulation and sluggish digestion simultaneously.

Like all medicines, Moza MPS 125/5mg Chewable Tablet 10s may cause side effects in some individuals.

Common Side Effects:

• Mild Abdominal Discomfort: Some patients may experience stomach discomfort, cramping, or loose stools.

• Nausea: Mild nausea may occur during the initial phase of treatment.

• Diarrhoea: Increased bowel movement frequency may occur due to enhanced gastrointestinal motility.

Uncommon Side Effects:

• Dry Mouth: Some individuals may experience mild dryness of the mouth.

• Headache: Mild headache or light-headedness may occasionally occur.

• Skin Rash: Mild allergic skin reactions or itching may occur in sensitive individuals.

Serious Side Effects (Require Immediate Medical Attention):

• Severe Allergic Reaction: Swelling of the face, lips, tongue, or throat with breathing difficulty requires urgent medical attention.

• Irregular Heartbeat: Rarely, mosapride may affect heart rhythm in susceptible individuals.

• Severe Persistent Diarrhoea or Abdominal Pain: Ongoing severe gastrointestinal symptoms should be reported promptly.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Take before meals or as directed by your doctor to improve gastrointestinal motility.

• Swallow the tablet or capsule whole with water.

• Take at the same time each day for consistent therapeutic benefit.

• Do not exceed the prescribed dose.

Moza MPS 125/5mg Chewable Tablet 10s works through complementary antiflatulent and prokinetic mechanisms.

Simethicone acts locally within the gastrointestinal tract by reducing the surface tension of gas bubbles. This allows smaller gas bubbles to combine into larger ones that can be expelled more easily through belching or flatulence, thereby relieving bloating and abdominal discomfort. Simethicone is not significantly absorbed into the bloodstream.

Mosapride is a selective serotonin 5-HT4 receptor agonist that stimulates the release of acetylcholine within the enteric nervous system. This enhances gastrointestinal motility, improves gastric emptying, and promotes coordinated movement of food through the digestive tract.

Together, simethicone and mosapride help relieve gas-related discomfort while improving digestive movement and reducing symptoms associated with functional dyspepsia and delayed gastric emptying.

A few practical measures can help improve treatment outcomes and ensure safe use of Moza MPS 125/5mg Chewable Tablet 10s:

• Take before meals: Mosapride works best when taken before food to improve gastric motility and digestion.

• Avoid overeating: Large meals may worsen bloating and indigestion despite treatment.

• Limit gas-forming foods: Reducing intake of carbonated drinks, beans, cabbage, and fried foods may improve symptoms.

• Maintain regular meal timings: Consistent eating patterns help support normal gastrointestinal motility.

• Avoid lying down immediately after meals: This may reduce reflux symptoms and post-meal discomfort.

• Inform your doctor about other gastrointestinal medicines: Certain antacids or motility agents may interact with mosapride.

Proper storage is important to maintain the stability and effectiveness of Moza MPS 125/5mg Chewable Tablet 10s:

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep in original packaging: Protects the medicine from humidity and environmental exposure.

• Keep out of reach of children: Store safely to prevent accidental ingestion.

• Check expiry before use: Do not use after the expiry date mentioned on the packaging.

Moza MPS 125/5mg Chewable Tablet 10s is generally not significantly affected by normal dietary intake. However:

• Take before meals: Mosapride is usually more effective when taken prior to meals.

• Avoid excessive alcohol: Alcohol may worsen bloating, gastric irritation, and reflux symptoms.

• Limit spicy and fatty foods: Such foods may aggravate indigestion, acidity, and delayed gastric emptying.

• Avoid excessive carbonated beverages: Fizzy drinks may increase gas formation and abdominal bloating.

Moza MPS 125/5mg Chewable Tablet 10s may interact with the following medicines:

• Anticholinergic Medicines: Drugs with anticholinergic effects may reduce the prokinetic action of mosapride.

• Other Prokinetic Agents: Concurrent use with similar gastrointestinal motility medicines may increase gastrointestinal side effects such as diarrhoea or abdominal cramps.

• QT-Prolonging Medicines: Caution is advised when combined with medicines that affect cardiac rhythm or prolong the QT interval.

• CYP3A4 Inhibitors: Medicines such as erythromycin or ketoconazole may alter mosapride metabolism and increase systemic exposure.

• Acid-Suppressing Medicines: Proton pump inhibitors and antacids are commonly co-prescribed and generally compatible, though dosing schedules may be adjusted by the doctor.

Moza MPS 125/5mg Chewable Tablet 10s should be used carefully in the following conditions:

• Gastrointestinal Obstruction: Mosapride stimulates gastrointestinal motility and should be used cautiously in patients with suspected intestinal obstruction or perforation.

• Severe Liver Impairment: Mosapride is metabolised in the liver; patients with hepatic dysfunction may require careful monitoring.

• Cardiac Arrhythmias: Although uncommon, caution is advised in patients with underlying cardiac rhythm disorders or electrolyte imbalance.

• Severe Renal Impairment: Patients with significant kidney dysfunction should use the medicine carefully under medical supervision.

• Functional Gastrointestinal Disorders: Persistent or unexplained abdominal pain, vomiting, or gastrointestinal bleeding should be medically evaluated before use.

Usually taken before meals as directed by your doctor. Dose and frequency depend on the severity of symptoms, the specific formulation, and the clinical condition being treated.

If a dose is missed, take it as soon as remembered. If it is almost time for the next dose, skip the missed dose and continue with the regular schedule. Do not double the dose to make up for a missed one.